AbCellera Biologics Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Net Income | $-146.4M | $-162.9M | $-146.4M | $158.5M | $153.5M | $118.9M | $-2.2M |
| Depreciation & Amortization | — | — | $24.4M | $27.8M | $14.5M | $4.8M | $1.6M |
| Depreciation | $18.4M | $12.5M | $12.8M | $9.0M | $4.4M | $2.3M | $1.6M |
| Amortization | $3.7M | $14.3M | $11.6M | $10.5M | $10.1M | $2.5M | $0 |
| Stock-Based Compensation | $55.8M | $67.6M | $64.2M | $49.5M | $30.6M | $8.4M | $890.0K |
| Net Cash from Operating Activities | $-131.3M | $-108.6M | $-43.9M | $277.4M | $244.6M | $22.7M | $2.7M |
| Investing Activities | |||||||
| Capital Expenditures | $42.8M | $78.4M | $76.9M | $70.7M | $58.5M | $9.7M | $4.0M |
| Business Acquisitions | — | — | $0 | $0 | $11.5M | $87.6M | — |
| Net Cash from Investing Activities | $87.8M | $121.4M | $-221.1M | $-352.6M | $-332.2M | $-119.8M | $-5.8M |
| Financing Activities | |||||||
| Dividends Paid | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $14.1M | $12.8M | $10.4M | $-1.6M | $-3.9M | $683.7M | $195.0K |
| Net Change in Cash | $-28.4M | $23.0M | $-254.0M | $-86.5M | $-93.0M | $586.6M | $-2.9M |
| Free Cash Flow | $-174.1M | $-187.0M | $-120.8M | $206.7M | $186.1M | $13.0M | $-1.3M |